MTS Medication Technologies Announces Postponement of Three- and Nine-Month Financial Results
Press Release: MTS Medication Technologies Announces Postponement of Three- and Nine-Month Financial Results
ST. PETERSBURG, Fla.--(BUSINESS WIRE)--MTS Medication Technologies, Inc. (NasdaqCM:MTSI) (www.mts-mt.com) today announced that the release of its three- and nine-month financial results that was scheduled for Tuesday, February 10, 2009 has been postponed until before the market opens on Tuesday, February 17, 2009. Management of the Company will host a conference call on that day at 11:00 AM EDT to discuss the Company’s earnings, financial results and achievements, which will be followed by a question and answer session with professional investors. Private investors are encouraged to email their questions in advance of the conference call to firstname.lastname@example.org or by facsimile to 727-573-1100. To access the conference call, please telephone 888-459-5609 and enter 83360289 for the conference ID number. A digital replay will be available and may be accessed by visiting the Company’s web site at www.mts-mt.com. About MTS Medication Technologies Founded in 1984, MTS Medication Technologies (www.mts-mt.com) is an international provider of medication adherence packaging systems designed to improve medication dispensing and administration. MTS manufactures automated packaging machines and related consumables for prescription medications and nutritional supplements. The Company serves approximately 8,000 pharmacies worldwide. This press release contains forward-looking information made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be affected by certain risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission (SEC) and actual results could differ materially from those set forth in forward-looking statements. Statements contained herein that are not historical facts are forward-looking statements and may include, but are not limited to, projections of revenue, income or losses, the value of contracts, capital expenditures, plans for future operations, the elimination of losses under certain programs, financing needs or plans, compliance with financial covenants in loan agreements, plans for sale of assets or businesses, plans relating to products or services of the Company, assessments of materiality, predictions of future events and the effects of pending and possible litigation, as well as assumptions relating to the foregoing. Other factors that could affect such differences include, but are not limited to, unanticipated increases in operating costs, labor disputes, capital requirements, increases in borrowing costs, product demand, pricing, market acceptance, intellectual property rights and litigation, risks in product and technology development and other risk factors detailed in the Company’s SEC filings. All statements regarding the marketing program resulting in increased sales are forward looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements. The Company undertakes no obligation to publicly release the result of any revisions of these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unexpected events.